Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer Clinical Trial

Official title:
A Multicenter, Open-label, Single-arm Study of Surufatinib in Combination With Tislelizumab for Second-line and Further Treatment of Metastatic Triple-negative Breast Cancer (TNBC)

Status Not yet recruiting

Clinical Trial Summary

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC). The study will be conducted in two parts; Safety lead-in phase and dose expansion phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Metastatic Triple-negative Breast Cancer
Triple Negative Breast Neoplasms

Clinical Trial Details

NCT number	NCT05746728
Study type	Interventional
Source	Tongji Hospital
Contact	Huihua Xiong, PI
Phone	027-83663405
Email	xionghuihua@hotmail.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	April 2023
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04986852` - Olinvacimab With Pembrolizumab in Patients With mTNBC	Phase 2
Recruiting	`NCT05831553` - TIP in Patients Affected by Metastatic TNBC
Recruiting	`NCT05570253` - A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer	Phase 2
Active, not recruiting	`NCT04454437` - Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments	Phase 2
Recruiting	`NCT05101096` - Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05227664` - A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer	Phase 2
Suspended	`NCT04250818` - Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
Completed	`NCT03004183` - SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC	Phase 2
Recruiting	`NCT06027268` - Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer	Phase 2
Recruiting	`NCT05089643` - Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer	Phase 2